Related Experiment Video

Updated: Jan 13, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.8K

BETting on the future: BET inhibition for patients with lymphoma

Timothy J Voorhees1, Catherine C Coombs2

  • 1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

Med (New York, N.Y.)
|January 10, 2026
PubMed

Insights

A novel BET inhibitor, TQB3617, shows promising safety and efficacy in a phase I study for patients with relapsed or refractory lymphoma. Further investigation is warranted for this new lymphoma therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Relapsed or refractory lymphoma necessitates novel therapeutic strategies.
  • Existing treatments for lymphoma may not be effective for all patients.

Purpose of the Study:

  • To evaluate the safety and efficacy of TQB3617, a novel BET inhibitor.
  • To determine the optimal dose for TQB3617 in a phase I dose-escalation study.

Main Methods:

  • Phase I dose-escalation study design.
  • Inclusion of patients with diverse lymphoma subtypes.
  • Assessment of safety, tolerability, and preliminary efficacy of TQB3617.

Main Results:

  • TQB3617 demonstrated a promising safety profile.
  • Preliminary efficacy was observed across various lymphoma subtypes, including T cell and Hodgkin lymphoma.
  • The study identified a tolerable dose range for further investigation.

Conclusions:

  • TQB3617 shows potential as a new treatment option for relapsed or refractory lymphoma.
  • Further clinical trials are justified to confirm the efficacy and safety of TQB3617.
  • BET inhibition represents a promising avenue for lymphoma treatment.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.5K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K